MacroGenics, Inc. is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops new therapeutic product candidates using its antibody-based technology platforms and also in partnership with other biopharmaceutical companies. The Company has a pipeline of product candidates in human clinical testing, primarily against various cancers. These include two product candidates developed using Fc Optimization platform, namely margetuximab, an antibody for the treatment of certain types of metastatic breast cancers and gastroesophageal cancers, and MGA271, an antibody to impact various tumors through multiple potential mechanisms of action. In addition, the Company has created different product candidates based on Dual-Affinity Re-Targetingr (DART) platform.
Rockville, US
Size (employees)
318 (est)+19%
MacroGenics is headquartered in Rockville, US

Key People at MacroGenics

Scott Koenig

Scott Koenig

President & Chief Executive Officer and Board Member
Heather Preston

Heather Preston

Observer of Boards
Ezio Bonvini

Ezio Bonvini

Senior Vice President, Research
Eric Risser

Eric Risser

Vice President, Development
James Karrels

James Karrels

Vice President, Chief Financial Officer
Lynn Cilinski

Lynn Cilinski

Vice President, Controller and Treasurer

MacroGenics Office Locations

MacroGenics has offices in Rockville, South San Francisco
Rockville, US (HQ)
9640 Medical Center Dr
Rockville, US
15235 Shady Grove Rd
South San Francisco, US
1 Corporate Dr

MacroGenics Metrics

MacroGenics Financial Metrics

Revenue (2016)

$91.9 m

Revenue growth (2015-16), %


Net income (2016)

($58.5 m)

Market capitalization (21-Mar-2017)

$645.3 m

Closing share price (21-Mar-2017)


Cash (31-Dec-2016)

$84.1 m
MacroGenics's current market capitalization is $645.3 m.
MacroGenics's revenue was reported to be $91.9 m in FY, 2016 which is a 8.9% decrease from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$58 m$47.8 m$100.9 m$91.9 m

Revenue growth, %


Operating expense total

$57.7 m$86.1 m$121 m$151.9 m


$366 k($38.3 m)($20.2 m)($60 m)

EBIT margin, %


Net Income

($260.8 k)($38.3 m)($20.1 m)($58.5 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$116.5 m$157.6 m$196.2 m$84.1 m

Accounts Receivable

$2 m$2.9 m$1.2 m$2.8 m


Current Assets

$119.5 m$164.7 m$342.4 m$283.9 m


$5 m$6.8 m$14.8 m$18 m

Total Assets

$125.8 m$173.9 m$359.3 m$311.3 m

Accounts Payable

$3.2 m$1.7 m$3 m$4 m

Current Liabilities

$28.8 m$27.1 m$23.3 m$27.3 m

Additional Paid-in Capital

$254.5 m$335.1 m$547.2 m$561.2 m

Retained Earnings

($175.7 m)($214 m)($234.2 m)($292.7 m)

Total Equity

$78.9 m$121.3 m$313.3 m$268.8 m

Financial Leverage

1.6 x1.4 x1.1 x1.2 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($260.8 k)($38.3 m)($20.1 m)($58.5 m)

Depreciation and Amortization

$1.2 m$1.8 m$2.9 m$7.6 m

Accounts Receivable

$42.2 k($931 k)$1.7 m($1.5 m)


Accounts Payable

($570.1 k)($1.5 m)($163 k)$2.2 m

Cash From Operating Activities

($14.2 m)($32.8 m)($13.7 m)($43.7 m)

Purchases of PP&E

($3 m)($3.6 m)($9.2 m)($11.4 m)

Cash From Investing Activities

($3 m)($3.6 m)($152.1 m)($70.2 m)

MacroGenics Market Value History

MacroGenics Online Presence

MacroGenics Company Life

You may also be interested in